查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008491

止吐药市场：2026-2032年全球市场预测（依适应症、药物类别、给药途径、最终用户和分销管道划分）

Antiemetic Drugs Market by Indication, Drug Class, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，止吐药市值将达到 64.4 亿美元，到 2026 年将成长到 70.1 亿美元，到 2032 年将达到 117.8 亿美元，复合年增长率为 9.00%。

主要市场统计数据
基准年 2025 64.4亿美元
预计年份：2026年 70.1亿美元
预测年份 2032 117.8亿美元
复合年增长率 (%) 9.00%

本次演讲将介绍止吐疗法，重点阐述其临床重要性、不断变化的患者需求以及创新与支持性护理的交汇点。

止吐治疗处于临床治疗、病患体验和商业策略的交会点。在现代肿瘤学、手术全期护理和放射治疗中，临床疗效、耐受性和生活品质日益受到重视，止吐药的作用也从辅助支持治疗转变为治疗路径的核心组成部分。因此，临床医生、保险公司和医疗服务提供者现在正从更广泛的观点评估止吐药的选择，包括给药的便利性、安全性以及与多方面支持治疗通讯协定的整合。

药物创新、数位医疗的整合以及治疗模式的转变，推动了止吐疗法的变革性变化。

止吐药领域正经历一场意义深远的变革，这主要得益于药理学、製剂科学和医疗服务模式的进步。近年来，更多标靶性药物和联合治疗相继问世，它们在增强止吐效果的同时，显着降低了副作用。这些药理学创新与製剂技术的改进相辅相成，提高了口服生物有效性，延长了治疗时间。因此，临床医师现在可以根据治疗强度、病患合併症和实际操作限制等因素，选择更合适的治疗方法。

评估 2025 年美国关税对止吐药供应链、定价趋势、策略采购和生产韧性的累积影响。

2025年实施的关税体系为包括止吐药在内的所有药品类别的供应链优化和商业规划引入了新的变数。进口关税和贸易政策的调整加剧了对全球筹资策略的审查，迫使製造商重新评估製造地。为此，多家公司加快制定紧急时应对计画，以减少对单一国家供应基地的依赖，并降低价格和前置作业时间波动带来的风险。

将适应症、药物分类、给药途径、终端用户行为和分销管道联繫起来的实用细分见解和策略规划指导。

市场细分为将临床需求转化为产品、市场准入和商业策略提供了一个实用的架构。根据适应症的不同，化疗引起的噁心呕吐、术后噁心呕吐和放射线治疗引起的噁心呕吐有不同的市场动态，每种适应症都有其独特的疗效、给药时间和安全性要求。化疗相关通讯协定通常需要合併多种药物进行预防性给药，并且需要可预测的药物动力学。对于术后用药，快速起效和适合短期住院至关重要。对于放射治疗相关的噁心，在分次放射治疗方案中可能需要长期控制。

区域洞察美洲、欧洲、中东和非洲以及亚太地区的趋势如何影响取得、报销、分销和临床引入。

区域趋势对止吐药的研发、核准、分销和应用等各方面都具有显着影响。在美洲，支付方的多样性以及公私采购体系的混合，奖励人们寻求能够减少后续医疗保健支出的证据。因此，处方集纳入止吐药往往受到医疗保健总成本和供应可靠性的考虑。在北美，门诊癌症治疗和日间手术的增加，推动了对方便口服製剂和适合居家服用的紧凑包装的需求。

来自主要企业的真知灼见，检验竞争定位、研发重点、策略联盟、製造地和商业化策略。

止吐药市场的竞争格局呈现出多种因素交织的态势，包括成熟疗法、学名药的竞争，以及透过新配方和联合治疗实现的渐进式创新。那些透过长效配方、固定剂量组合药物或便利包装等方式维持差异化价值提案的公司，往往能够获得优先采购权和临床医师的支持。在研发、生产和分销管道之间建立策略联盟，能够进一步加速市场进入，并降低执行风险。

为优先加强供应韧性、加速招募、优化分销和以患者为中心的创新提出切实可行的建议。

领导者应优先考虑几项影响深远的倡议，以维持药品供应、支持临床医生并创造商业性价值。首先，透过供应商多元化、建立策略性区域伙伴关係以及使用库存视觉化工具来增强价值链韧性，从而能够快速应对各种突发情况。其次，加速开发以患者为中心的製剂和包装，以支持门诊和居家照护下的给药，从而使产品特性与不断发展的护理路径保持一致。

稳健的调查方法，结合了与专家的直接参与、对第二手资料的系统性审查、资料三角验证、检验以及对限制的揭露。

本报告的分析整合了结构化的初级和二级调查方法，以确保方法的严谨性和实际相关性。初级研究包括对临床专业人员、采购经理和销售主管的访谈，以获取有关处方行为、采购重点和供应链限制因素的第一手资讯。二级研究包括同行评审文献、临床指南分析、监管文件和公开的政策声明，以阐明临床和政策驱动因素的背景。

为了使相关人员能够充分了解止吐领域的挑战和机会，我们总结了策略挑战、优先事项和考虑因素，形成了简洁扼要的结论。

止吐治疗领域融合了临床需求、不断演变的给药模式和复杂的商业性环境，因此需要明确的策略规划。能够根据不断变化的医疗环境（尤其是门诊和居家给药）调整产品特性，同时增强供应韧性的利益相关人员，更有能力满足临床医生和支付方的期望。此外，提供能够量化以患者为中心的获益和营运成本降低的证据，仍然是将产品纳入处方药目录和获得合约的有力工具。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：止吐药市场：依适应症划分

  • 化疗引起的噁心和呕吐
  • 术后噁心呕吐
  • 放射线治疗引起的噁心和呕吐

第九章：止吐药市场：依药物类别划分

  • 皮质类固醇
  • 多巴胺拮抗剂
  • 神经激肽1受体拮抗剂
  • 血清素5-HT3受体拮抗剂

第十章：止吐药市场：依给药途径划分

  • 静脉
  • 口服

第十一章 止吐药市场：依最终用户划分

  • 诊所
  • 居家照护设施
  • 医院

第十二章：止吐药市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 止吐药市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：止吐药市场：依类别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 止吐药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国止吐药市场

第十七章：中国止吐药市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Acacia Pharma Limited
  • Akorn Operating Company LLC
  • Algen Healthcare Ltd.
  • Alkem Laboratories Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Fresenius Kabi Pte Ltd.
  • Glenmark Pharmaceuticals Limited
  • Global Calcium Private Limited
  • Helsinn Healthcare SA
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Merck KGaA
  • Novartis AG
  • Pax Healthcare
  • Pfizer Inc.
  • Sanofi SA
  • Saphnix Life Sciences
  • Scindia Pharma
  • Sun Pharmaceutical Industries Limited
  • Swastik Life Sciences
  • Teva Pharmaceuticals Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Weefsel Pharma
Product Code: MRR-C002B1C996F2

The Antiemetic Drugs Market was valued at USD 6.44 billion in 2025 and is projected to grow to USD 7.01 billion in 2026, with a CAGR of 9.00%, reaching USD 11.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.44 billion
Estimated Year [2026] USD 7.01 billion
Forecast Year [2032] USD 11.78 billion
CAGR (%) 9.00%

Introduces antiemetic therapeutics, highlighting clinical importance, evolving patient needs, and the intersection of innovation and supportive care

Antiemetic therapeutics sit at the intersection of clinical care, patient experience, and commercial strategy. Modern oncology, perioperative medicine, and radiation therapy increasingly emphasize not only clinical efficacy but also tolerability and quality of life, elevating the role of antiemetics from supportive adjuncts to core components of treatment pathways. As a result, clinicians, payers, and providers now evaluate antiemetic choices through a broader lens that includes administration convenience, safety profiles, and integration with multimodal supportive care protocols.

Moreover, shifts in care delivery-most notably the expansion of outpatient chemotherapy, home-based infusion services, and ambulatory surgery centers-have altered expectations for route of administration and product packaging. Patients and clinicians demand reliable oral options that preserve efficacy while enabling adherence outside the hospital, and health systems prioritize interventions that reduce readmissions and improve throughput. Consequently, manufacturers and distributors must adapt commercial models to align with evolving procurement processes and clinician workflows.

Finally, regulatory clarity and guideline updates have reinforced evidence-driven prescribing, while reimbursement and contracting environments continue to shape formulary decisions. Taken together, these forces create both constraints and opportunities for developers, suppliers, and health systems seeking to improve supportive care outcomes and operational efficiency.

Transformative shifts in antiemetic therapy driven by pharmacologic innovation, digital care integration, and changing delivery models

The antiemetic landscape is undergoing substantive transformation driven by advances in pharmacology, formulation science, and care delivery models. Recent years have produced more targeted agents and combination regimens that enhance emetic control while reducing adverse effects, and these pharmacologic innovations are complemented by formulation improvements that expand oral bioavailability and prolong therapeutic windows. As a result, clinicians can select regimens that better match treatment intensity, patient comorbidities, and logistical constraints.

Concurrently, care models are shifting toward patient-centric approaches. Telehealth-enabled follow-up, remote symptom monitoring, and digital adherence tools are increasingly used to capture real-world tolerability and to guide supportive interventions. These digital adjuncts allow for earlier identification of breakthrough nausea and enable timely escalation or modification of antiemetic therapy, improving outcomes and reducing the burden on acute care services. Parallel to this, supply chain resilience and strategic sourcing have risen as priorities for manufacturers and health systems, prompting investment in regional manufacturing capacity and diversified supplier networks.

In addition, payer and hospital procurement strategies now center on total cost of care metrics and patient-reported outcomes. This change favors interventions that reduce downstream resource utilization, such as unscheduled clinic visits and prolonged hospital stays, thereby elevating the commercial value of antiemetics that demonstrably improve tolerability and adherence. Collectively, these shifts are reshaping clinical practice and the competitive landscape, requiring stakeholders to realign R&D, market access, and commercialization strategies.

Assessing the cumulative impact of United States tariffs in 2025 on antiemetic supply chains, pricing dynamics, strategic sourcing, and manufacturing resilience

The tariff landscape introduced in 2025 ushered in a new set of variables for supply chain optimization and commercial planning across pharmaceutical categories, including antiemetics. Import duties and trade policy adjustments have increased scrutiny of global sourcing strategies, prompting manufacturers to re-evaluate where active pharmaceutical ingredients, excipients, and finished-dose manufacturing occur. In response, several firms accelerated contingency planning to reduce dependence on single-country supply nodes and to mitigate price and lead-time volatility.

Consequently, procurement teams and contract manufacturers have prioritized supplier diversification and dual-sourcing arrangements to preserve continuity of supply. These actions include qualification of regional contract manufacturing organizations, increased inventory buffering for critical components, and renegotiation of long-term contracts to incorporate tariff contingency clauses. At the same time, regulatory and quality oversight remain central; localization efforts must satisfy stringent manufacturing standards while minimizing disruptions to existing regulatory filings and distribution agreements.

From a strategic perspective, companies have adopted multiple risk-mitigation tactics that include nearshoring select production steps, investing in supply visibility tools, and coordinating closely with distribution partners to optimize route-to-market logistics. Payers and health systems, for their part, are increasingly focused on predictable supply and stable pricing as criteria for formulary placement and preferred contracting. In sum, the cumulative tariff impacts of 2025 have strengthened incentives for resilient, transparent, and regionally balanced manufacturing and procurement strategies.

Actionable segmentation insights connecting indication, drug class, administration route, end user behavior, and distribution channel guidance for strategy

Segmentation provides a practical framework to translate clinical needs into product, access, and commercial strategies. Based on Indication, market dynamics differ across chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, and radiation-induced nausea and vomiting, each presenting unique efficacy, timing, and safety imperatives. Chemotherapy-associated protocols often require multi-agent prophylaxis and predictable pharmacokinetics; post-operative use emphasizes rapid onset and suitability for short-stay settings; radiation-related nausea may demand extended-duration control for fractionated regimens.

Based on Drug Class, decision criteria and formulary placement pivot on attributes of corticosteroids, dopamine antagonists, neurokinin 1 receptor antagonists, and serotonin 5-HT3 receptor antagonists, with each class offering distinct benefit-risk trade-offs that influence regimen selection and combination approaches. Corticosteroids provide broad antiemetic augmentation but carry systemic effects that must be managed. Dopamine antagonists supply alternative mechanisms but demand attention to neurologic tolerability. Neurokinin 1 receptor antagonists and serotonin 5-HT3 receptor antagonists remain foundational for guideline-driven prophylaxis, and evolving formulations aim to optimize adherence and convenience.

Based on Route Of Administration, outcomes and channel strategies diverge between intravenous and oral options, shaping procurement preferences in hospitals and outpatient settings and influencing product development priorities. Based on End User, clinics, home care settings, and hospitals each impose different stocking practices, dispensing workflows, and clinician touchpoints that affect uptake and adherence. Based on Distribution Channel, hospital pharmacy, online pharmacy, and retail pharmacy routes carry distinct reimbursement pathways, inventory models, and patient access considerations that determine where and how products gain traction. By integrating these segmentation lenses, stakeholders can align clinical evidence generation, commercial messaging, and distribution tactics to the real-world requirements of each use case.

Regional insights on how Americas, Europe, Middle East & Africa, and Asia-Pacific dynamics influence access, reimbursement, distribution, and clinical adoption

Regional dynamics materially influence every aspect of antiemetic development, approval, distribution, and adoption. In the Americas, diverse payer landscapes and a mix of public and private procurement systems create incentives for evidence demonstrating reductions in downstream healthcare utilization; consequently, formulary positioning often hinges on total cost of care narratives and supply reliability. In North America, outpatient oncology and ambulatory surgery growth have elevated demand for convenient oral options and compact packaging suited to home administration.

In Europe, Middle East & Africa, regulatory harmonization across jurisdictions and national procurement processes shape entry strategies, with reimbursement timelines and health technology assessment outcomes guiding commercialization sequencing. Local manufacturing and distribution partnerships frequently reduce lead times and support compliance with regional procurement rules, and in some countries system-level purchasing emphasizes affordable, generic-friendly options.

In Asia-Pacific, rapid expansion of oncology services, increased uptake of outpatient care models, and heterogeneous regulatory pathways present both opportunity and complexity. Investment in regional manufacturing infrastructure and strategic partnerships can accelerate access, while tailored clinical evidence that reflects local treatment paradigms supports uptake. Across all regions, distribution channel evolution and digital health adoption vary markedly, and stakeholders must calibrate pricing, stakeholder engagement, and supply strategies to local drivers to secure sustainable access and clinical integration.

Key company insights examining competitive positioning, R&D priorities, strategic partnerships, manufacturing footprint, and commercialization strategies

Competitive dynamics in the antiemetic space reflect a blend of established therapeutic classes, generics competition, and incremental innovation through new formulations and combination regimens. Companies that sustain differentiated value propositions-whether through long-acting formulations, fixed-dose combinations, or convenience-focused packaging-tend to secure preferential procurement and clinician loyalty. Strategic partnerships across development, manufacturing, and distribution channels further accelerate market entry and reduce execution risk.

R&D priorities now emphasize not only mechanistic efficacy but also tolerability, dosing convenience, and evidence of downstream healthcare savings. This shift has stimulated cross-functional collaborations between clinical teams and real-world evidence groups to capture patient-reported outcomes and healthcare utilization endpoints. In addition, manufacturing footprint and supply chain transparency have become competitive differentiators; companies that can demonstrate robust, diversified supply and quick replenishment capabilities gain favor with large hospital systems and integrated delivery networks.

Commercial models increasingly blend direct-to-provider engagement, digital tools to support patient adherence, and targeted contracting with payers and group purchasing organizations. Firms that articulate clear value across clinical, operational, and economic dimensions, and that can adapt to regional procurement nuances, will be better positioned to convert clinical advantage into sustainable commercial performance.

Actionable recommendations to strengthen supply resilience, accelerate adoption, optimize distribution, and prioritize patient-centric innovation

Leaders should prioritize a short set of high-impact actions to preserve access, support clinicians, and capture commercial value. First, reinforce supply chain resilience through supplier diversification, strategic regional partnerships, and inventory visibility tools that enable rapid response to disruption. Second, accelerate development of patient-centric formulations and packaging that support outpatient and home-care administration, thereby aligning product attributes with evolving care pathways.

Third, invest in evidence generation that demonstrates not only symptom control but also reductions in downstream resource use and improvements in patient-reported outcomes; such evidence strengthens negotiations with payers and hospital procurement teams. Fourth, deploy digital adherence and remote monitoring solutions to support real-world use, reduce breakthrough events, and collect post-launch data that inform iterative product positioning. Fifth, refine commercial approaches to suit distribution channels-hospital pharmacy, online pharmacy, and retail pharmacy-ensuring that reimbursement, logistics, and clinician engagement align with channel-specific expectations.

Finally, integrate tariff and trade policy risk into strategic planning by considering nearshoring, contractual tariff protections, and scenario-based financial modeling. By sequencing these actions with clear owners and measurable KPIs, organizations can move from reactive to proactive management of clinical, operational, and commercial risks.

Robust research methodology combining primary expert engagement, structured secondary review, data triangulation, validation, and limitation disclosure

The analysis underpinning this report integrates structured primary and secondary research practices to ensure methodological rigor and practical relevance. Primary inputs include interviews with clinical experts, procurement leaders, and commercial executives to capture experiential insights on prescribing behavior, purchasing priorities, and supply chain constraints. Secondary review comprises peer-reviewed literature, clinical guideline analyses, regulatory documentation, and publicly available policy statements to contextualize clinical and policy drivers.

Data triangulation is applied across sources to validate thematic findings and to reconcile divergent perspectives. Quality controls included standardized interview guides, independent coding of qualitative inputs, and cross-verification of critical claims with multiple expert respondents. Limitations are acknowledged, including potential variability in regional practice patterns and the evolving nature of policy interventions. These limitations are disclosed transparently, and findings are presented with caveats where applicable to support informed decision-making.

Concise conclusion synthesizing strategic imperatives, priorities, and considerations to guide stakeholders through antiemetic challenges and opportunities

The antiemetic therapeutic area presents a convergence of clinical need, delivery model change, and commercial complexity that demands strategic clarity. Stakeholders who align product attributes with evolving care settings-particularly outpatient and home-based administration-while reinforcing supply resilience will be better positioned to meet clinician and payer expectations. Meanwhile, evidence generation that quantifies patient-centered benefits and operational savings remains a powerful lever for formulary inclusion and contracting.

Looking ahead, organizations should balance near-term operational actions with longer-term investments in formulation innovation and digital support tools. By doing so, they can reduce acute care utilization, improve patient adherence, and create defensible differentiation against generic competition. Ultimately, the most successful stakeholders will be those that integrate clinical insight, supply chain agility, and pragmatic commercialization into a cohesive strategy that responds to both immediate pressures and enduring patient needs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiemetic Drugs Market, by Indication

  • 8.1. Chemotherapy-Induced Nausea And Vomiting
  • 8.2. Post-Operative Nausea And Vomiting
  • 8.3. Radiation-Induced Nausea And Vomiting

9. Antiemetic Drugs Market, by Drug Class

  • 9.1. Corticosteroids
  • 9.2. Dopamine Antagonists
  • 9.3. Neurokinin 1 Receptor Antagonists
  • 9.4. Serotonin 5-HT3 Receptor Antagonists

10. Antiemetic Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral

11. Antiemetic Drugs Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care Settings
  • 11.3. Hospitals

12. Antiemetic Drugs Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Antiemetic Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antiemetic Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antiemetic Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Antiemetic Drugs Market

17. China Antiemetic Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Acacia Pharma Limited
  • 18.6. Akorn Operating Company LLC
  • 18.7. Algen Healthcare Ltd.
  • 18.8. Alkem Laboratories Ltd.
  • 18.9. Cipla Limited
  • 18.10. Dr. Reddy's Laboratories Limited
  • 18.11. Fresenius Kabi Pte Ltd.
  • 18.12. Glenmark Pharmaceuticals Limited
  • 18.13. Global Calcium Private Limited
  • 18.14. Helsinn Healthcare S.A.
  • 18.15. Hikma Pharmaceuticals PLC
  • 18.16. Lupin Limited
  • 18.17. Merck KGaA
  • 18.18. Novartis AG
  • 18.19. Pax Healthcare
  • 18.20. Pfizer Inc.
  • 18.21. Sanofi S.A.
  • 18.22. Saphnix Life Sciences
  • 18.23. Scindia Pharma
  • 18.24. Sun Pharmaceutical Industries Limited
  • 18.25. Swastik Life Sciences
  • 18.26. Teva Pharmaceuticals Industries Ltd.
  • 18.27. Torrent Pharmaceuticals Ltd.
  • 18.28. Viatris Inc.
  • 18.29. Weefsel Pharma

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIEMETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIEMETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY POST-OPERATIVE NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RADIATION-INDUCED NAUSEA AND VOMITING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DOPAMINE ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY NEUROKININ 1 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. GCC ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GCC ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. GCC ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. GCC ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GCC ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. G7 ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. G7 ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. G7 ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. G7 ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. G7 ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. NATO ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. NATO ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. NATO ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. NATO ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. NATO ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ANTIEMETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA ANTIEMETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA ANTIEMETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)